Skip Navigation

COVID-19 Update

We are vaccinating patients ages 12+. Learn more:

Vaccines | Testing | Patient Care | Visitor Guidelines | Coronavirus | Self-Checker |  Email Alerts

Emily Ann Kendall, M.D., Ph.D.

Headshot of Emily Ann Kendall
  • Assistant Professor of Medicine

Languages: English, German, Spanish

Research Interests

Infectious disease dynamics; tuberculosis; drug resistance; treatment and regimen development; mechanistic modeling more


The Johns Hopkins Hospital

600 N. Wolfe Street
Baltimore, MD 21287 map


Dr. Emily Kendall is an Assistant Professor of Medicine in the Infectious Diseases division at the Johns Hopkins University School of Medicine. Her research focuses on infectious diseases dynamics and antibiotic resistance.

Her current work focuses on understanding tuberculosis transmission, treatment outcomes, and regimen development. She uses mathematical models and computational approaches to guide optimal use of drug regimens and other tools for more effectively combating tuberculosis on the level of individual patients and large-scale epidemics. 

Dr. Kendall received her B.A. from Harvard University and her M.D. from the Vanderbilt University School of Medicine. She completed her residency at Massachusetts General Hospital and a fellowship in infectious diseases at Johns Hopkins. more


  • Assistant Professor of Medicine

Departments / Divisions

Centers & Institutes



  • MD; Vanderbilt University School of Medicine (2010)


  • Internal Medicine; Massachusetts General Hospital (2013)


  • Infectious Diseases; Johns Hopkins University School of Medicine (2016)

Board Certifications

  • American Board of Internal Medicine (Infectious Disease) (2015)
  • American Board of Internal Medicine (Internal Medicine) (2013)

Research & Publications


Lab Website: Emily Kendall Lab

Selected Publications

Kendall EA, Fojo AT, Dowdy DW. Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysis. Lancet Respir Med. 2017 Mar;5(3):191-199. 

Kendall EA, Shrestha S, Cohen T, Nuermberger E, Dooley KE, Gonzalez-Angulo L, Churchyard GJ, Nahid P, Rich ML, Bansbach C, Forissier T, Lienhardt C, Dowdy DW. Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model. PLoS Med. 2017 Jan 3;14(1):e1002202. 

Kendall EA, Azman AS, Cobelens FG, Dowdy DW. MDR-TB treatment as prevention: The projected population-level impact of expanded treatment for multidrug-resistant tuberculosis. PLoS One. 2017 Mar 8;12(3):e0172748

Kendall EA, Cohen T, Mitnick CD, Dowdy DW. Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective. Int J Infect Dis. 2017 Mar;56:185-189.

Kendall EA, Fofana MO, Dowdy DW. “Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis.” Lancet Respir Med. 2015 Dec;3(12):963-72. doi: 10.1016/S2213-2600(15)00458-0. Epub 2015 Nov 18.

Contact for Research Inquiries

1500 Orleans Street
CRB2 Room 106
Baltimore, MD 21287 map

Patient Ratings & Comments

The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

  • ...Loading ratings...
  • ... 
  • ... 
  • ... 
  • ... 
  • ... 


Is this you? Edit Profile
back to top button